Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 8/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29291675 | 0.84 | HDAC6 (0.56) | HDAC6HDAC1HDAC8HDAC5CNR2 | |
| SCHEMBL29291673 | 0.84 | HDAC6 (0.56) | HDAC6HDAC1HDAC8HDAC5CNR2 | |
| SCHEMBL2570723 | 0.80 | MAPT (0.49) | HDAC6HDAC1HDAC8HDAC5CNR2 | |
| SCHEMBL2570725 | 0.80 | MAPT (0.49) | HDAC6HDAC1HDAC8HDAC5CNR2 | |
| SCHEMBL6994953 | 0.77 | P2RX7 (0.37) | HDAC6CNR2PTGER2PTGER3CYP2C8 | |
| SCHEMBL16691755 | 0.76 | HDAC1 (0.46) | HDAC6HDAC1HDAC8HDAC5CNR2 | |
| SCHEMBL9101843 | 0.75 | HDAC6 (0.55) | HDAC6HDAC1HDAC8HDAC5CNR2 | |
| SCHEMBL2571004 | 0.75 | HDAC6 (0.55) | HDAC6HDAC1HDAC8HDAC5CNR2 | |
| SCHEMBL28693724 | 0.73 | HDAC6 (0.51) | HDAC6HDAC1HDAC8HDAC5CNR2 | |
| SCHEMBL16692964 | 0.73 | HDAC6 (0.51) | HDAC6HDAC1HDAC8HDAC5CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147371-A1 | OXADIAZOLINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147371-A1 | OXADIAZOLINE DERIVATIVES | DDT, FOXO3, PDCD4 | HDAC6 215/4885HDAC1 516/4885HDAC8 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.